Phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Manegold, C.
Digumarti, R.
Zukin, M.
de Marinis, F.
Mellerngaard, A.
Gandara, D.
Simms, L.
Kaiser, C.
Blatter, J.
Gatzemeier, U.
机构：
[1] Med Ctr Univ Mannheim, Interdisciplinary Thorac Oncol, Mannheim, Germany
[2] Nizams Inst Med Sci, Hyderabad, Andhra Pradesh, India
[3] Natl Canc Inst, Rio De Janeiro, Brazil
[4] San Camillo Forlanini Hosp, Lung Dis Dept, Rome, Italy
[5] Herlev Univ Hosp, DK-2730 Herlev, Denmark
[6] Univ Calif Davis, Davis Canc Ctr, Sacramento, CA 95817 USA
[7] Eli Lilly & Co, Toronto, ON, Canada
[8] Eli Lilly & Co, Indianapolis, IN USA
[9] Eli Lilly Deutschland GMBH, Bad Homburg, Germany
[10] Hosp Grosshansdorf, Grosshansdorf, Germany
来源：
EJC SUPPLEMENTS | 2007年 / 5卷 / 06期
关键词：
D O I：
10.1016/S1359-6349(07)70101-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1BA
引用
收藏
页码：9 / 9
页数：1
相关论文
共 50 条
  • [31] Cost-effectiveness of Gemcitabine (Gemzar™) plus cisplatin versus etoposide plus cisplatin for advanced non small cell lung cancer (NSCLC) in Spain
    Rosell, R
    Sacristan, JA
    Duthie, T
    Cardenal, F
    Artal, A
    Carrato, A
    Lomas, M
    Barneto, I
    Bameto, I
    Massuti, B
    [J]. ANNALS OF ONCOLOGY, 1998, 9 : 92 - 93
  • [32] RETROSPECTIVE ANALYSIS OF SAFETY AND EFFICACY OUTCOMES FOR ELDERLY PATIENTS IN THE RANDOMIZED PHASE III TRIAL OF CISPLATIN/PEMETREXED VERSUS CISPLATIN/GEMCITABINE IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Syrigos, K. N.
    Martins, R. G.
    Blatter, J.
    Simms, L.
    Scagliotti, G.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 98 - 98
  • [33] Gemcitabine plus cisplatin in patients with state IIIB/IV non-small cell lung cancer (NSCLC)
    Teixeira, Encarnacao
    Goncalves, Ines
    Mayor, Renato Sotto
    Melo, Ricardo
    Lopes, Carlos
    Pinto, Ana
    [J]. ANNALS OF ONCOLOGY, 2004, 15 : 194 - 194
  • [34] Phase III study of Lipoplatin plus Gemcitabine versus Cisplatin plus Gemcitabine in advanced NSCLC; interim analysis
    Kosmas, C.
    Angel, J.
    Athanasiou, A.
    Rapti, A.
    Karanikas, C.
    Lambaki, S.
    Politis, N.
    Mylonakis, N.
    [J]. EJC SUPPLEMENTS, 2009, 7 (02): : 531 - 531
  • [35] Concurrent biweekly gemcitabine plus cisplatin chemotherapy and radiotherapy in patients with locally advanced non-small cell lung cancer
    Jung, M
    Kim, H
    Oak, C
    Jang, T
    Jeon, Y
    Jung, T
    [J]. LUNG CANCER, 2005, 49 : S170 - S170
  • [36] A phase I dose escalation study of sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer (NSCLC)
    Reck, M.
    Frickhofen, N.
    Gatzemeier, U.
    Fuhr, H.
    Lanzalone, S.
    Lechuga, M. J.
    Wang, E.
    Chao, R.
    Felip, E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [37] Phase 2 study of pemetrexed and cisplatin plus either enzastaurin or placebo in chemonaive patients with advanced NSCLC
    Reck, M.
    Ramlau, R.
    Von Pawel, J.
    Antonio, B. San
    Visseren-Grul, C.
    Chouaki, N.
    Eschbach, C.
    Szczesna, A.
    Vansteenkiste, J.
    [J]. EJC SUPPLEMENTS, 2009, 7 (02): : 528 - 528
  • [38] Gemcitabine and cisplatin for advanced non-small cell lung cancer (NSCLC)
    Casal, J
    Grande, C
    Caeiro, M
    [J]. EUROPEAN JOURNAL OF CANCER, 1997, 33 : 1083 - 1083
  • [39] Second line treatment with irinotecan plus cisplatin versus cisplatin of patients with advanced non-small cell lung cancer pretreated with taxanes and gemcitabine: A multicenter randomized phase III study
    Agelidou, A.
    Syrigos, K.
    Rapti, A.
    Agelidou, M.
    Polyzos, A.
    Athanasiadis, A.
    Tselepatiotis, E.
    Androulakis, N.
    Kalbakis, K.
    Samonis, G.
    [J]. ANNALS OF ONCOLOGY, 2004, 15 : 167 - 167
  • [40] THE COSTS OF TREATING PATIENTS WITH ADVANCED OR RECURRENT NON-SMALL CELL CANCER (NSCLC) WITH BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE COMPARED WITH PEMETREXED PLUS CISPLATIN IN INDUCTION AND MAINTENANCE THERAPY IN GERMANY AND ITALY
    Nuijten, M.
    [J]. VALUE IN HEALTH, 2009, 12 (03) : A41 - A41
12345